Top

21-04-2015 | Osteoporosis | Review | Article

A look behind the scenes: the risk and pathogenesis of primary osteoporosis

Journal: Nature Reviews Rheumatology

Authors: Gretl Hendrickx, Eveline Boudin, Wim Van Hul

Publisher: Nature Publishing Group UK

Abstract

Osteoporosis is a common disorder, affecting hundreds of millions of people worldwide, and characterized by decreased bone mineral density and increased fracture risk. Known nonheritable risk factors for primary osteoporosis include advanced age, sex-steroid deficiency and increased oxidative stress. Age is a nonmodifiable risk factor, but the influence of a person's lifestyle (diet and physical activity) on their bone structure and density is modifiable to some extent. Heritable factors influencing bone fragility can be monogenic or polygenic. Osteogenesis imperfecta, juvenile osteoporosis and syndromes of decreased bone density are discussed as examples of monogenic disorders associated with bone fragility. So far, the factors associated with polygenic osteoporosis have been investigated mainly in genome-wide association studies. However, epigenetic mechanisms also contribute to the heritability of polygenic osteoporosis. Identification of these heritable and nonheritable risk factors has already led to the discovery of therapeutic targets for osteoporosis, which emphasizes the importance of research into the pathogenetic mechanisms of osteoporosis. Accordingly, this article discusses the many heritable and nonheritable factors that contribute to the pathogenesis of primary osteoporosis. Although osteoporosis can also develop secondary to many other diseases or their treatment, a discussion of the factors that contribute only to secondary osteoporosis is beyond the scope of this Review.

Nat Rev Rheumatol 2015;11:462–474. doi:10.1038/nrrheum.2015.48

Abrahamsen, B., van Staa, T., Ariely, R., Olson, M. & Cooper, C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos. Int. 20, 1633–1650 (2009).CrossRefPubMed

van den Bergh, J. P., van Geel, T. A. & Geusens, P. P. Osteoporosis, frailty and fracture: implications for case finding and therapy. Nat. Rev. Rheumatol. 8, 163–172 (2012).CrossRefPubMed

Melton, L. J. 3rd. How many women have osteoporosis now? J. Bone Miner. Res. 10, 175–177 (1995).CrossRefPubMed

Randell, A. et al. Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos. Int. 5, 427–432 (1995).CrossRefPubMed

Kanis, J. A. & Johnell, O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos. Int. 16, 229–238 (2005).CrossRefPubMed

Bachrach, L. K. Acquisition of optimal bone mass in childhood and adolescence. Trends Endocrinol. Metab. 12, 22–28 (2001).CrossRefPubMed

Sapir-Koren, R. & Livshits, G. Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles? Osteoporos. Int. (2014).

Zuo, C. et al. Osteoblastogenesis regulation signals in bone remodeling. Osteoporos. Int. 23, 1653–1663 (2012).CrossRefPubMed

Garnero, P. The contribution of collagen crosslinks to bone strength. Bonekey Rep. 1, 182 (2012).CrossRefPubMedPubMedCentral

10.

Alliston, T. Biological regulation of bone quality. Curr. Osteoporos. Rep. 12, 366–375 (2014).CrossRefPubMedPubMedCentral

11.

Sroga, G. E. & Vashishth, D. Effects of bone matrix proteins on fracture and fragility in osteoporosis. Curr. Osteoporos. Rep. 10, 141–150 (2012).CrossRefPubMedPubMedCentral

12.

Bouxsein, M. L. & Karasik, D. Bone geometry and skeletal fragility. Curr. Osteoporos. Rep. 4, 49–56 (2006).CrossRefPubMed

13.

Almeida, M. Aging mechanisms in bone. Bonekey Rep. 1, 102 (2012).CrossRefPubMedPubMedCentral

14.

Manolagas, S. C. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr. Rev. 31, 266–300 (2010).CrossRefPubMedPubMedCentral

15.

de Boer, J. et al. Premature aging in mice deficient in DNA repair and transcription. Science 296, 1276–1279 (2002).CrossRefPubMed

16.

Tyner, S. D. et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 415, 45–53 (2002).CrossRefPubMed

17.

Nojiri, H. et al. Cytoplasmic superoxide causes bone fragility owing to low-turnover osteoporosis and impaired collagen cross-linking. J. Bone Miner. Res. 26, 2682–2694 (2011).CrossRefPubMed

18.

Smietana, M. J., Arruda, E. M., Faulkner, J. A., Brooks, S. V. & Larkin, L. M. Reactive oxygen species on bone mineral density and mechanics in Cu, Zn superoxide dismutase (Sod1) knockout mice. Biochem. Biophys. Res. Commun. 403, 149–153 (2010).CrossRefPubMedPubMedCentral

19.

Ambrogini, E. et al. FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab. 11, 136–146 (2010).CrossRefPubMedPubMedCentral

20.

Almeida, M. Unraveling the role of FoxOs in bone—insights from mouse models. Bone 49, 319–327 (2011).CrossRefPubMedPubMedCentral

21.

Almeida, M., Han, L., Martin-Millan, M., O'Brien, C. A. & Manolagas, S. C. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting β-catenin from T cell factor- to forkhead box O-mediated transcription. J. Biol. Chem. 282, 27298–27305 (2007).CrossRefPubMed

22.

Essers, M. A. et al. Functional interaction between β-catenin and FOXO in oxidative stress signaling. Science 308, 1181–1184 (2005).CrossRefPubMed

23.

Migliaccio, E. et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 402, 309–313 (1999).CrossRefPubMed

24.

Nemoto, S. & Finkel, T. Redox regulation of forkhead proteins through a p66^shc-dependent signaling pathway. Science 295, 2450–2452 (2002).CrossRefPubMed

25.

Giorgio, M. et al. Electron. transfer between cytochrome c and p66^Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 122, 221–233 (2005).CrossRefPubMed

26.

Pacini, S. et al. p66^SHC promotes apoptosis and antagonizes mitogenic signaling in T cells. Mol. Cell Biol. 24, 1747–1757 (2004).CrossRefPubMedPubMedCentral

27.

Bartell, S. M. et al. Deletion of the redox amplifier p66^shc decreases ROS production in murine bone and increases osteoblast resistance to oxidative stress and bone mass [abstract]. J. Bone Miner. Res. 26 (Suppl. 1), S85 (2011).

28.

Maier, B. et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev. 18, 306–319 (2004).CrossRefPubMedPubMedCentral

29.

Wang, X. et al. p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J. Cell Biol. 172, 115–125 (2006).CrossRefPubMedPubMedCentral

30.

Jilka, R. L. et al. Dysfunctional osteocytes increase RANKL and promote cortical pore formation in their vicinity: a mechanistic explanation for the development of cortical porosity with age [abstract]. J. Bone Miner. Res. 27 (Suppl. 1), S348 (2012).

31.

Jilka, R. L. et al. Dysapoptosis of osteoblasts and osteocytes increases cancellous bone formation but exaggerates bone porosity with age. J. Bone Miner. Res. 29, 103–117 (2014).CrossRefPubMed

32.

Tomkinson, A., Gevers, E. F., Wit, J. M., Reeve, J. & Noble, B. S. The role of estrogen in the control of rat osteocyte apoptosis. J. Bone Miner. Res. 13, 1243–1250 (1998).CrossRefPubMed

33.

Almeida, M. et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J. Biol. Chem. 282, 27285–27297 (2007).CrossRefPubMed

34.

Tomkinson, A., Reeve, J., Shaw, R. W. & Noble, B. S. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J. Clin. Endocrinol. Metab. 82, 3128–3135 (1997).PubMed

35.

Frost, H. M. Micropetrosis. J. Bone Joint Surg. Am. 42-A, 144–150 (1960).

36.

Busse, B. et al. Decrease in the osteocyte lacunar density accompanied by hypermineralized lacunar occlusion reveals failure and delay of remodeling in aged human bone. Aging Cell 9, 1065–1075 (2010).CrossRefPubMed

37.

Carpentier, V. T. et al. Increased proportion of hypermineralized osteocyte lacunae in osteoporotic and osteoarthritic human trabecular bone: implications for bone remodeling. Bone 50, 688–694 (2012).CrossRefPubMed

38.

Manolagas, S. C., O'Brien, C. A. & Almeida, M. The role of estrogen and androgen receptors in bone health and disease. Nat. Rev. Endocrinol. 9, 699–712 (2013).CrossRefPubMedPubMedCentral

39.

Seeman, E. Periosteal bone formation—a neglected determinant of bone strength. N. Engl. J. Med. 349, 320–323 (2003).CrossRefPubMed

40.

Martin-Millan, M. et al. The estrogen receptor-α in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol. Endocrinol. 24, 323–334 (2010).CrossRefPubMedPubMedCentral

41.

Nakamura, T. et al. Estrogen prevents bone loss via estrogen receptor α and induction of Fas ligand in osteoclasts. Cell 130, 811–823 (2007).CrossRefPubMed

42.

Chiang, C. et al. Mineralization and bone resorption are regulated by the androgen receptor in male mice. J. Bone Miner. Res. 24, 621–631 (2009).CrossRefPubMed

43.

Notini, A. J. et al. Osteoblast deletion of exon 3 of the androgen receptor gene results in trabecular bone loss in adult male mice. J. Bone Miner. Res. 22, 347–356 (2007).CrossRefPubMed

44.

Sinnesael, M. et al. Androgen receptor (AR) in osteocytes is important for the maintenance of male skeletal integrity: evidence from targeted AR disruption in mouse osteocytes. J. Bone Miner. Res. 27, 2535–2543 (2012).CrossRefPubMed

45.

Almeida, M. et al. Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERα. J. Bone Miner. Res. 25, 769–781 (2010).PubMed

46.

Kousteni, S. et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104, 719–730 (2001).PubMed

47.

Kousteni, S. et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298, 843–846 (2002).CrossRefPubMed

48.

Marathe, N., Rangaswami, H., Zhuang, S., Boss, G. R. & Pilz, R. B. Pro-survival effects of 17β-estradiol on osteocytes are mediated by nitric oxide/cGMP via differential actions of cGMP-dependent protein kinases I and II. J. Biol. Chem. 287, 978–988 (2012).CrossRefPubMed

49.

Seeman, E. Pathogenesis of bone fragility in women and men. Lancet 359, 1841–1850 (2002).CrossRefPubMed

50.

Kaufman, J. M. & Vermeulen, A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 26, 833–876 (2005).CrossRefPubMed

51.

Shahnazari, M. et al. Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice. Bone 50, 628–637 (2012).CrossRefPubMed

52.

Syed, F. A. et al. Effects of chronic estrogen treatment on modulating age-related bone loss in female mice. J. Bone Miner. Res. 25, 2438–2446 (2010).CrossRefPubMedPubMedCentral

53.

Zebaze, R. M. et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 375, 1729–1736 (2010).CrossRefPubMed

54.

Manolagas, S. C. & Parfitt, A. M. For whom the bell tolls: distress signals from long-lived osteocytes and the pathogenesis of metabolic bone diseases. Bone 54, 272–278 (2013).CrossRefPubMed

55.

Hocking, L. J., Whitehouse, C. & Helfrich, M. H. Autophagy: a new player in skeletal maintenance? J. Bone Miner. Res. 27, 1439–1447 (2012).CrossRefPubMed

56.

Kim, K. H. & Lee, M. S. Autophagy—a key player in cellular and body metabolism. Nat. Rev. Endocrinol. 10, 322–337 (2014).CrossRefPubMed

57.

Zhang, L. et al. Pathway-based genome-wide association analysis identified the importance of regulation-of-autophagy pathway for ultradistal radius BMD. J. Bone Miner. Res. 25, 1572–1580 (2010).CrossRefPubMedPubMedCentral

58.

Rubinsztein, D. C., Marino, G. & Kroemer, G. Autophagy and aging. Cell 146, 682–695 (2011).CrossRefPubMed

59.

Selman, C. et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 326, 140–144 (2009).CrossRefPubMedPubMedCentral

60.

Chang, Y. Y. et al. Nutrient-dependent regulation of autophagy through the target of rapamycin pathway. Biochem. Soc. Trans. 37, 232–236 (2009).CrossRefPubMed

61.

DeSelm, C. J. et al. Autophagy proteins regulate the secretory component of osteoclastic bone resorption. Dev. Cell 21, 966–974 (2011).CrossRefPubMedPubMedCentral

62.

Liu, F. et al. Suppression of autophagy by FIP200 deletion leads to osteopenia in mice through the inhibition of osteoblast terminal differentiation. J. Bone Miner. Res. 28, 2414–2430 (2013).CrossRefPubMed

63.

Onal, M. et al. Suppression of autophagy in osteocytes mimics skeletal aging. J. Biol. Chem. 288, 17432–17440 (2013).CrossRefPubMedPubMedCentral

64.

Bonjour, J. P., Kraenzlin, M., Levasseur, R., Warren, M. & Whiting, S. Dairy in adulthood: from foods to nutrient interactions on bone and skeletal muscle health. J. Am. Coll. Nutr. 32, 251–263 (2013).CrossRefPubMedPubMedCentral

65.

Christodoulou, S., Goula, T., Ververidis, A. & Drosos, G. Vitamin D and bone disease. Biomed. Res. Int. 2013, 396541 (2013).CrossRefPubMed

66.

Eisman, J. A. & Bouillon, R. Vitamin D: direct effects of vitamin D metabolites on bone: lessons from genetically modified mice. Bonekey Rep. 3, 499 (2014).CrossRefPubMedPubMedCentral

67.

Rajendran, P. et al. Antioxidants and human diseases. Clin. Chim. Acta 436C, 332–347 (2014).

68.

Shen, C. L. et al. Fruits and dietary phytochemicals in bone protection. Nutr. Res. 32, 897–910 (2012).CrossRefPubMed

69.

Li, J. J. et al. Fruit and vegetable intake and bone mass in Chinese adolescents, young and postmenopausal women. Public Health Nutr. 16, 78–86 (2013).CrossRefPubMed

70.

New, S. A. et al. Dietary influences on bone mass and bone metabolism: further evidence of a positive link between fruit and vegetable consumption and bone health? Am. J. Clin. Nutr. 71, 142–151 (2000).CrossRefPubMed

71.

Prynne, C. J. et al. Fruit and vegetable intakes and bone mineral status: a cross sectional study in 5 age and sex cohorts. Am. J. Clin. Nutr. 83, 1420–1428 (2006).CrossRefPubMed

72.

Zalloua, P. A. et al. Impact of seafood and fruit consumption on bone mineral density. Maturitas 56, 1–11 (2007).CrossRefPubMed

73.

Heaney, R. P. & Layman, D. K. Amount and type of protein influences bone health. Am. J. Clin. Nutr. 87, 1567S–1570S (2008).CrossRefPubMed

74.

Sebastian, A. Dietary protein content and the diet's net acid load: opposing effects on bone health. Am. J. Clin. Nutr. 82, 921–922 (2005).CrossRefPubMed

75.

Bonjour, J. P. Nutritional disturbance in acid-base balance and osteoporosis: a hypothesis that disregards the essential homeostatic role of the kidney. Br. J. Nutr. 110, 1168–1177 (2013).CrossRefPubMedPubMedCentral

76.

Bushinsky, D. A. Metabolic alkalosis decreases bone calcium efflux by suppressing osteoclasts and stimulating osteoblasts. Am. J. Physiol. 271, F216–F222 (1996).CrossRefPubMed

77.

Leeuwenburgh, C. & Heinecke, J. W. Oxidative stress and antioxidants in exercise. Curr. Med. Chem. 8, 829–838 (2001).CrossRefPubMed

78.

Ozcivici, E. et al. Mechanical signals as anabolic agents in bone. Nat. Rev. Rheumatol. 6, 50–59 (2010).CrossRefPubMedPubMedCentral

79.

Rochefort, G. Y., Pallu, S. & Benhamou, C. L. Osteocyte: the unrecognized side of bone tissue. Osteoporos. Int. 21, 1457–1469 (2010).CrossRefPubMed

80.

Balemans, W. et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10, 537–543 (2001).CrossRefPubMed

81.

Balemans, W. et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39, 91–97 (2002).CrossRefPubMedPubMedCentral

82.

Li, X. et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280, 19883–19887 (2005).CrossRefPubMed

83.

Semenov, M., Tamai, K. & He, X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem. 280, 26770–26775 (2005).CrossRefPubMed

84.

Boudin, E., Fijalkowski, I., Piters, E. & Van Hul, W. The role of extracellular modulators of canonical Wnt signaling in bone metabolism and diseases. Semin. Arthritis Rheum. 43, 220–240 (2013).CrossRefPubMed

85.

Wang, Y. et al. Wnt and the Wnt signaling pathway in bone development and disease. Front. Biosci. (Landmark Ed.) 19, 379–407 (2014).CrossRef

86.

Maurel, D. B., Boisseau, N., Benhamou, C. L. & Jaffre, C. Alcohol and bone: review of dose effects and mechanisms. Osteoporos. Int. 23, 1–16 (2012).CrossRefPubMed

87.

Ronis, M. J., Mercer, K. & Chen, J. R. Effects of nutrition and alcohol consumption on bone loss. Curr. Osteoporos. Rep. 9, 53–59 (2011).CrossRefPubMedPubMedCentral

88.

Chen, J. R. et al. A role for ethanol-induced oxidative stress in controlling lineage commitment of mesenchymal stromal cells through inhibition of Wnt/β-catenin signaling. J. Bone Miner. Res. 25, 1117–1127 (2010).CrossRefPubMed

89.

Chen, J. R., Shankar, K., Nagarajan, S., Badger, T. M. & Ronis, M. J. Protective effects of estradiol on ethanol-induced bone loss involve inhibition of reactive oxygen species generation in osteoblasts and downstream activation of the extracellular signal-regulated kinase/signal transducer and activator of transcription 3/receptor activator of nuclear factor-κB ligand signaling cascade. J. Pharmacol. Exp. Ther. 324, 50–59 (2008).CrossRefPubMed

90.

Kanis, J. A. et al. Smoking and fracture risk: a meta-analysis. Osteoporos. Int. 16, 155–162 (2005).CrossRefPubMed

91.

Ward, K. D. & Klesges, R. C. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif. Tissue Int. 68, 259–270 (2001).CrossRefPubMedPubMedCentral

92.

Yoon, V., Maalouf, N. M. & Sakhaee, K. The effects of smoking on bone metabolism. Osteoporos. Int. 23, 2081–2092 (2012).CrossRefPubMed

93.

Marini, J. C. & Blissett, A. R. New genes in bone development: what's new in osteogenesis imperfecta. J. Clin. Endocrinol. Metab. 98, 3095–3103 (2013).CrossRefPubMedPubMedCentral

94.

Sillence, D. O., Senn, A. & Danks, D. M. Genetic heterogeneity in osteogenesis imperfecta. J. Med. Genet. 16, 101–116 (1979).CrossRefPubMedPubMedCentral

95.

OMIM^® Online Mendelian Inheritance in Man^®. An Online Catalog of Human Genes and Genetic Disorders [online], (2015).

96.

Van Dijk, F. S. & Sillence, D. O. Osteogenesis imperfecta: Clinical diagnosis, nomenclature and severity assessment. Am. J. Med. Genet. A 164, 1470–1481 (2014).CrossRefPubMedCentral

97.

Lazarus, S., Zankl, A. & Duncan, E. L. Next-generation sequencing: a frameshift in skeletal dysplasia gene discovery. Osteoporos. Int. 25, 407–422 (2014).CrossRefPubMed

98.

Warman, M. L. et al. Nosology and classification of genetic skeletal disorders: 2010 revision. Am. J. Med. Genet. A 155A, 943–968 (2011).CrossRefPubMed

99.

van Dijk, F. S. et al. EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. Eur. J. Hum. Genet. 20, 11–19 (2012).CrossRefPubMed

100.

Lazarus, S., Moffatt, P., Duncan, E. L. & Thomas, G. P. A brilliant breakthrough in OI type V. Osteoporos. Int. 25, 399–405 (2014).CrossRefPubMed

101.

Eyre, D. R. & Weis, M. A. Bone collagen: new clues to its mineralization mechanism from recessive osteogenesis imperfecta. Calcif. Tissue Int. 93, 338–347 (2013).CrossRefPubMedPubMedCentral

102.

Gebken, J. et al. Increased cell surface expression of receptors for transforming growth factor-β on osteoblasts from patients with Osteogenesis imperfecta. Pathobiology 68, 106–112 (2000).CrossRefPubMed

103.

Grafe, I. et al. Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta. Nat. Med. 20, 670–675 (2014).CrossRefPubMedPubMedCentral

104.

Lapunzina, P. et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am. J. Hum. Genet. 87, 110–114 (2010).CrossRefPubMedPubMedCentral

105.

Keupp, K. et al. Mutations in WNT1 cause different forms of bone fragility. Am. J. Hum. Genet. 92, 565–574 (2013).CrossRefPubMedPubMedCentral

106.

Laine, C. M. et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N. Engl. J. Med. 368, 1809–1816 (2013).CrossRefPubMedPubMedCentral

107.

Fahiminiya, S. et al. Whole-exome sequencing reveals a heterozygous LRP5 mutation in a 6-year-old boy with vertebral compression fractures and low trabecular bone density. Bone 57, 41–46 (2013).CrossRefPubMed

108.

Korvala, J. et al. Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity. BMC Med. Genet. 13, 26 (2012).CrossRefPubMedPubMedCentral

109.

Crabbe, P. et al. Missense mutations in LRP5 are not a common cause of idiopathic osteoporosis in adult men. J. Bone Miner. Res. 20, 1951–1959 (2005).CrossRefPubMed

110.

van Dijk, F. S. et al. PLS3 mutations in X-linked osteoporosis with fractures. N. Engl. J. Med. 369, 1529–1536 (2013).CrossRefPubMed

111.

Fahiminiya, S. et al. Osteoporosis caused by mutations in PLS3: clinical and bone tissue characteristics. J. Bone Miner. Res. 29, 1805–1814 (2014).CrossRefPubMed

112.

Laine, C. M. et al. Primary osteoporosis without features of OI in children and adolescents: clinical and genetic characteristics. Am. J. Med. Genet. A 158A, 1252–1261 (2012).CrossRefPubMed

113.

Gong, Y. et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513–523 (2001).CrossRefPubMed

114.

Narumi, S. et al. Various types of LRP5 mutations in four patients with osteoporosis-pseudoglioma syndrome: identification of a 7.2-kb microdeletion using oligonucleotide tiling microarray. Am. J. Med. Genet. A 152A, 133–140 (2010).CrossRefPubMed

115.

Balemans, W. & Van Hul, W. The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes. Endocrinology 148, 2622–2629 (2007).CrossRefPubMed

116.

Puig-Hervas, M. T. et al. Mutations in PLOD2 cause autosomal-recessive connective tissue disorders within the Bruck syndrome—osteogenesis imperfecta phenotypic spectrum. Hum. Mutat. 33, 1444–1449 (2012).CrossRefPubMed

117.

Shaheen, R. et al. Mutations in FKBP10 cause both Bruck syndrome and isolated osteogenesis imperfecta in humans. Am. J. Med. Genet. A 155A, 1448–1452 (2011).CrossRefPubMed

118.

Schwarze, U. et al. Mutations in FKBP10, which result in Bruck syndrome and recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide lysines in bone collagen. Hum. Mol. Genet. 22, 1–17 (2013).CrossRefPubMed

119.

Peacock, M., Turner, C. H., Econs, M. J. & Foroud, T. Genetics of osteoporosis. Endocr. Rev. 23, 303–326 (2002).CrossRefPubMed

120.

Siris, E. S. et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286, 2815–2822 (2001).CrossRefPubMed

121.

Duncan, E. L. & Brown, M. A. Clinical review 2: Genetic determinants of bone density and fracture risk—state of the art and future directions. J. Clin. Endocrinol. Metab. 95, 2576–2587 (2010).CrossRefPubMed

122.

Ralston, S. H. & Uitterlinden, A. G. Genetics of osteoporosis. Endocr. Rev. 31, 629–662 (2010).CrossRefPubMed

123.

Duncan, E. L. et al. Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet. 7, e1001372 (2011).CrossRefPubMedPubMedCentral

124.

Estrada, K. et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat. Genet. 44, 491–501 (2012).CrossRefPubMedPubMedCentral

125.

Medina-Gomez, C. et al. Meta-analysis of genome-wide scans for total body BMD in children and adults reveals allelic heterogeneity and age-specific effects at the WNT16 locus. PLoS Genet. 8, e1002718 (2012).CrossRefPubMedPubMedCentral

126.

Richards, J. B. et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 371, 1505–1512 (2008).CrossRefPubMedPubMedCentral

127.

Rivadeneira, F. et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat. Genet. 41, 1199–1206 (2009).CrossRefPubMedPubMedCentral

128.

Styrkarsdottir, U. et al. Multiple genetic loci for bone mineral density and fractures. N. Engl. J. Med. 358, 2355–2365 (2008).CrossRefPubMed

129.

Styrkarsdottir, U. et al. European bone mineral density loci are also associated with BMD in East-Asian populations. PLoS ONE 5, e13217 (2010).CrossRefPubMedPubMedCentral

130.

Zhang, L. et al. Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. Hum. Mol. Genet. 23, 1923–1933 (2014).CrossRefPubMed

131.

Moayyeri, A. et al. Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium. Hum. Mol. Genet. 23, 3054–3068 (2014).CrossRefPubMedPubMedCentral

132.

Oei, L. et al. Genome-wide association study for radiographic vertebral fractures: a potential role for the 16q24 BMD locus. Bone 59, 20–27 (2014).CrossRefPubMedPubMedCentral

133.

Oei, L. et al. A genome-wide copy number association study of osteoporotic fractures points to the 6p25.1 locus. J. Med. Genet. 51, 122–131 (2014).CrossRefPubMed

134.

Chew, S. et al. Homozygous deletion of the UGT2B17 gene is not associated with osteoporosis risk in elderly Caucasian women. Osteoporos. Int. 22, 1981–1986 (2011).CrossRefPubMed

135.

Deng, F. Y. et al. Genome-wide copy number variation association study suggested VPS13B gene for osteoporosis in Caucasians. Osteoporos. Int. 21, 579–587 (2010).CrossRefPubMed

136.

Yang, T. L. et al. Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis. Am. J. Hum. Genet. 83, 663–674 (2008).CrossRefPubMedPubMedCentral

137.

Holroyd, C., Harvey, N., Dennison, E. & Cooper, C. Epigenetic influences in the developmental origins of osteoporosis. Osteoporos. Int. 23, 401–410 (2012).CrossRefPubMed

138.

Vrtacnik, P., Marc, J. & Ostanek, B. Epigenetic mechanisms in bone. Clin. Chem. Lab. Med. 52, 589–608 (2014).CrossRefPubMed

139.

Delgado-Calle, J., Garmilla, P. & Riancho, J. A. Do epigenetic marks govern bone mass and homeostasis? Curr. Genomics 13, 252–263 (2012).CrossRefPubMedPubMedCentral

140.

Cohen-Kfir, E. et al. Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. Endocrinology 152, 4514–4524 (2011).CrossRefPubMed

141.

Redfern, A. D. et al. RNA-induced silencing complex (RISC) proteins PACT, TRBP, and Dicer are SRA binding nuclear receptor coregulators. Proc. Natl Acad. Sci. USA 110, 6536–6541 (2013).CrossRefPubMedPubMedCentral

142.

van Wijnen, A. J. et al. MicroRNA functions in osteogenesis and dysfunctions in osteoporosis. Curr. Osteoporos. Rep. 11, 72–82 (2013).CrossRefPubMedPubMedCentral

143.

Gamez, B., Rodriguez-Carballo, E. & Ventura, F. MicroRNAs and post-transcriptional regulation of skeletal development. J. Mol. Endocrinol. 52, R179–197 (2014).CrossRefPubMed

144.

Delgado-Calle, J. et al. DNA methylation contributes to the regulation of sclerostin expression in human osteocytes. J. Bone Miner. Res. 27, 926–937 (2012).CrossRefPubMed

145.

Delgado-Calle, J. et al. Role of DNA methylation in the regulation of the RANKL-OPG system in human bone. Epigenetics 7, 83–91 (2012).CrossRefPubMedPubMedCentral

146.

Gelb, B. D., Shi, G. P., Chapman, H. A., & Desnick, R. J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273, 1236–1238 (1996).CrossRefPubMed

147.

Fijalkowski, I., Boudin, E., Mortier, G. & van Hul, W. Sclerosing bone dysplasias: leads toward novel osteoporosis treatments. Curr. Osteoporos. Rep. 12, 243–251 (2014).CrossRefPubMed

148.

Tella, S. H. & Gallagher, J. C. Biological agents in management of osteoporosis. Eur. J. Clin. Pharmacol. (2014).

149.

McClung, M. R. et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412–420 (2014).CrossRefPubMed

150.

Recker, R. et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J. Bone Miner. Res. 30, 216–224 (2015).CrossRefPubMed

Medicine Matters Rheumatology

Abstract